Otsuka Pharmaceutical is increasing its attain into uncommon illnesses, getting into into an settlement to accumulate Jnana Therapeutics and its lead drug candidate, a small molecule shifting towards pivotal testing in a metabolic dysfunction for which few therapies can be found. Beneath the phrases of the deal introduced Thursday, Otsuka pays $800 million upfront to purchase Boston-based Jnana. The Japanese […]